Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 7: | Line 7: | ||
*[[Castleman disease]] | *[[Castleman disease]] | ||
*[[Erdheim-Chester disease]] | *[[Erdheim-Chester disease]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| Line 24: | Line 26: | ||
[[Category:Castleman disease medications]] | [[Category:Castleman disease medications]] | ||
[[Category:Erdheim-Chester disease medications]] | [[Category:Erdheim-Chester disease medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Hodgkin lymphoma medications (historic)]] |
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] | ||
Revision as of 01:42, 29 April 2022
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Diseases for which it was used
Also known as
- Code names: AY 22989, SILA 9268A, SLM, WY-090217
- Generic names: RAPA, rapamycin
- Brand name: Rapamune